Find a Doctor

Robert D. Toto

University Of Texas Southwestern Medical Center
Nephrology, Internal Medicine
Male
Practicing approx. 44 years

Bio


Robert Toto is an Internal Medicine specialist and a Nephrologist in Dallas, Texas. He has been an author on 147 peer reviewed articles and participated in 1 clinical trial in the past 15 years. He is licensed to treat patients in TX.

Contact

2201 Inwood Rd
Dallas, TX 75235, US

Latest Advances


Latest Advance
Study
  • Condition: Chronic Kidney Disease
  • Journal: The lancet. Diabetes & endocrinology
  • Treatment Used: Dapagliflozin
  • Number of Patients: 4304
  • Published —
This study evaluated the effects of dapagliflozin on major adverse kidney and cardiovascular (heart and vessels) events in patients with diabetic and non-diabetic chronic kidney disease (when the kidneys are damaged and can’t filter blood the way they should).
Latest Advance
Study
  • Condition: Reduced Kidney Function
  • Journal: Diabetes care
  • Treatment Used: Linagliptin
  • Number of Patients: 6979
  • Published —
The study researched the safety of linagliptin in patients with reduced kidney function.
Latest Advance
Study
  • Condition: Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
  • Journal: Cardiorenal medicine
  • Treatment Used: Bardoxolone Methyl (Bard)
  • Number of Patients: 2185
  • Published —
This study characterized reductions in magnesium with bardoxolone methyl (Bard) in patients with type 2 diabetes.
Latest Advance
Study
  • Condition: Heart Failure (HF) and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk
  • Journal: Circulation
  • Treatment Used: Linagliptin
  • Number of Patients: 6979
  • Published —
This study analyzed heart failure (HF) and related outcomes with the dipeptidyl peptidase-4 inhibitor linagliptin versus placebo in participants with type 2 diabetes mellitus and atherosclerotic cardiovascular disease and/or kidney disease.
Latest Advance
Study
  • Condition: Anemia in Patients with Type 2 Diabetes and Chronic Kidney Disease
  • Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation
  • Treatment Used: Darbepoetin Prior to Dialysis Initiation
  • Number of Patients: 590
  • Published —
This study determined whether treatment of anemia before dialysis therapy initiation with erythropoiesis-stimulating agents alters outcomes in patients with type 2 diabetes and chronic kidney disease.
Latest Advance
Study
  • Condition: Cardiovascular events and renal risk among patients with type 2 diabetes
  • Journal: JAMA
  • Treatment Used: Linagliptin
  • Number of Patients: 6979
  • Published —
Patients with type 2 diabetes have an increased risk of having cardiovascular events (CV, or incidents that involve damage to the heart muscle) and renal risk (disease of the kidney). This study evaluated the effectiveness of linagliptin, a drug that lowers blood glucose levels.
Latest Advance
Study
  • Condition: Early Diabetic Kidney Disease
  • Journal: Diabetes, obesity & metabolism
  • Treatment Used: Linagliptin
  • Number of Patients: 360
  • Published —
This study tested the safety and efficacy of using linagliptin to treat patients with early diabetic kidney disease.

Clinical Trials


Clinical Trial
  • Status: Recruiting
  • Intervention Type: Procedure
  • Participants: 1000
  • Start Date: September 1, 2019
Kidney Precision Medicine Project

All Publications
View All


Publication
Study
  • Journal: Kidney medicine
  • Published —
Alport Syndrome Classification and Management.

Contact

2201 Inwood Rd
Dallas, TX 75235, US

Affiliations

  • Ut Southwestern University Hospital - William P. Clements Jr.

Credentials

  • Graduate InstitutionIllinois Medical College
    1977
  • Licenses
    Internal Medicine in TX
  • Board Certifications
    Nephrology
    Internal Medicine

Insurance

Contact them to find out if they accept your insurance plan.